Relevance. The combination of coronavirus disease (COVID-19) with arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) is associated with decreased saturation, general clinical signs of inflammation, coagulopathies and worsens the course and prognosis of the disease. That is why it is important to identify all possible risk factors for complicated pathology for the prevention and timely treatment of this category of patients.
Objective: to study the feature of coronavirus disease in patients with AH and COPD.
Materials and methods. A total of 101 patients aged 30 to 80 years with COVID-19 were examined. The first group included 26 people with COVID-19 and COPD (GOLD 2, groups A, B), and the second group included 75 patients with COVID-19 and AH (I-III stages, 1-3 grade). The parameters of the general blood test, biochemical blood test, coagulation testing, D-dimer, C-reactive protein (CRP), and ferritin in the blood were studied.
Results. Patients with COVID-19 and COPD had higher erythrocyte sedimentation rate (p> 0,05) and leukocytosis (p <0,05), as well as increased concentrations of creatinine (p < 0,05) and urea (p < 0,01) that indicates the presence of renal pathology. Patients with COVID-19 and AH had significantly lower prothrombin time (p < 0,05) and international normalized ratio (p < 0,05), as well as a higher prothrombin index (p <0,05), which indicates the benefits of the procoagulant properties of blood in this category of patients. The level of D-dimer (p> 0,05), CRP (p> 0,05), and ferritin (p <0,05) was higher in patients of the 2nd group, which indicates a more severe course of coronavirus disease, as well as more high risks of thromboembolic complications.
Conclusions. The features of coronavirus disease in patients with hypertension indicate a more severe course of the pathology and a high risk of thromboembolic complications, as evidenced by the procoagulant properties of blood and a high level of D-dimer, CRP, and ferritin. According to the data of clinical and laboratory examinations in patients with COPD and COVID-19, there was a significant increase in creatinine, urea, and leukocytosis, which may indicate the addition of renal pathology.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health. 2020; 13(12):1833-1839. DOI: 10.1016/J.JIPH.2020.07.014
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402107/
Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. American Journal of Hypertension. 2020; 33(5):373-374. DOI: 10.1093/AJH/HPAA057
Publisher Site: https://academic.oup.com/ajh/article/33/5/373/5816609
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184512/
Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgraduate medicine. 2020; 132(8):749-755. DOI: 10.1080/00325481.2020.1786964
Higham A, Mathioudakis A, Vestbo J, Singh D. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. European Respiratory Review: an Official Journal of the European Respiratory Society. 2020; 29(158):200199. DOI: 10.1183/16000617.0199-2020
Publisher Site: https://err.ersjournals.com/content/29/158/200199
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651840/
Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, Kario K, Kishi T, Mogi M, Nishiyama A, Ohishi M, Ohkubo T, Tamura K, Tanaka M, Yamamoto E, Yamamoto K, Itoh H. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertension research : official journal of the Japanese Society of Hypertension. 2020; 43(10):1028-1046. DOI: 10.1038/s41440-020-0515-0
Publisher Site: https://www.nature.com/articles/s41440-020-0515-0
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393334/
Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of microbiology, immunology, and infection. 2020; 53(3):425-435. DOI: 10.1016/J.JMII.2020.04.015
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201239/
Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert review of hematology. 2020; 13(11):1265-1275. DOI: 10.1080/17474086.2020.1831383
Cheng L, Li H, Li L, Liu C, Yan S, Chen H, Li Y. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of clinical laboratory analysis. 2020; 34(10):e23618. DOI: 10.1002/JCLA.23618
Publisher Site: https://onlinelibrary.wiley.com/doi/10.1002/jcla.23618
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595919/
This work is licensed under a Creative Commons Attribution 4.0 International License.